0.527
-0.012
(-2.23%)
Jun 19 - Close
NYSEMKT
real-time data -
Disclaimer
Currency in USD
| Range | 0.52 - 0.55 |
| 52 week | 0.41 - 0.84 |
| Open | 0.55 |
| Vol / Avg. | 0.00/632,913.00 |
| Mkt cap | 84.01M |
| P/E | - |
| Div/yield | - |
| EPS | -0.37 |
| Shares | 159.41M |
| Beta | 0.72 |
| Inst. own | 20% |
Key stats and ratios
| Q3 (Sep '12) | 2011 | |
| Net profit margin | -192.79% | -76.76% |
| Operating margin | -182.43% | -73.98% |
| EBITD margin | - | -35.44% |
| Return on average assets | -25.70% | -37.93% |
| Return on average equity | -81.17% | -86.32% |
| Employees | 507 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 350, 420 Lexington Avenue
NEW YORK, NY 10170
United States - Map
+1-212-5844180 (Phone)
+1-646-5147787 (Fax)
NEW YORK, NY 10170
United States - Map
+1-212-5844180 (Phone)
+1-646-5147787 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
NeoStem, Inc. operates in cellular therapy industry. Cellular therapy addresses the process by which new cells are introduced into a tissue to prevent or treat disease, or regenerate damaged or aged tissue, and consists of a separate therapeutic technology platform in addition to pharmaceuticals, biologics and medical devices. The Company�s business model includes the development of novel cell therapy products, as well as operating a contract development and manufacturing organization (CDMO) providing services to others in the regenerative medicine industry. Progenitor Cell Therapy, LLC, the Company�s wholly owned subsidiary (PCT), is a CDMO in the cellular therapy industry. PCT has provided pre-clinical and clinical current Good Manufacturing Practice (cGMP) development and manufacturing services to over 100 clients advancing regenerative medicine product candidates through rigorous quality standards all the way through to human testing.
Officers and directors
| Robin L. Smith M.D. | Chairman of the Board, Chief Executive Officer | |
| Lawrence A. May M.D. | Chief Financial Officer, Vice President | |
| Robert A. Preti Ph.D. | President and Chief Scientific Officer - PCT | |
| Joseph Talamo | Vice President, Chief Accounting Officer, Corporate Controller | |
| Catherine M. Vaczy Esq | Vice President, General Counsel | |
| Andrew L. Pecora M.D. | Chief Medical Officer, Director | |
| Eric H.C. Wei | Director | |
| Richard L. Berman | Independent Director | |
| Drew Bernstein CPA | Independent Director | |
| Martyn D. Greenacre | Independent Director |